Clinical trial NCT04622111: Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers.
Official title: One Centre, Single Ascending Dose and Double Blind Multiple Ascending Dose, Safety and Pharmacokinetics Phase I Study of CPL207280 Compound in Healthy Volunteers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Celon Pharma SA
Sponsor class: INDUSTRY
Collaborators: name: National Center for Research and Development, Poland
First posted: 2020-11-09
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The planned study is to determine the safety and pharmacokinetic properties of CPL207280 compound after single and multiple (two weeks) administration in healthy volunteers.

Detailed description: This is to be one-centre, single ascending dose and double-blind multiple ascending dose two part study of CPL207280 compound in healthy volunteers. PART A is a single dose, open-label part with CPL207280 compound administered with dose escalation between cohorts.Additionaly assessing the effect of food and effect of metformin on bioavailability of CPL207280 is to be done in additional cohort. PART B is a multiple, double-blind part with CPL207280 compound administered for 14 days with dose escalation between cohorts. Participants in this part are to be randomized to receive Investigational Medicinal Product (IMP) or placebo in 3:1 ratio. Safety and pharmacokinetic properties of CPL207280 compound is to be determined following different doses in single oral IMP administration in PART A and different doses of IMP administered orally for two weeks in PART B.

Eligibility criteria: Inclusion Criteria:

* Caucasian female or male
* Body-mass index (BMI): ≥ 18.5 kg/m² and \< 29.9 kg/m²,
* Physical examination without any clinically relevant abnormality,
* Clinical laboratory results in hematology or renal/hepatic test and clinical laboratory results in other tests without any clinically relevant abnormalities as assessed by Investigator,
* Non-smoker and non-user of tobacco products for at least 3 months before screening,
* Subject able to provide written informed consent after receiving information about the trial,
* Informed Consent Form signed and dated prior to Screening evaluations,
* Ability and willingness to comply with the requirements of the study protocol,
* Volunteer (or his/her partner) of childbearing potential willingness to use acceptable forms of contraception.

Exclusion Criteria:

* Known allergy, hypersensitivity, intolerance or contraindication to other drugs similar in structure or class to CPL207280 compound, or to any excipients of the formulation,
* Any known significant current or past acute or chronic disease or condition of the: circulatory, respiratory, hematopoietic, endocrine, nervous and musculoskeletal system, alimentary and urinary tracts, allergic disease, genetic or psychiatric disorder that could influence the present general health condition, at the Investigator's discretion,
* A long QT interval analysis syndrome (in the interview) or is under the treatment with antiarrhythmic drugs,
* Current disease of the alimentary tract, liver or kidneys that may influence absorption, distribution and/or elimination of the studied drug, as assessed by the Investigator and documented in the medical history,
* Medical condition that requires administration of other drugs or use of any drug within the 4 weeks preceding the first IMP administration and during the entire study. Drugs commonly used with fast metabolism may be administered and is up to Investigator discretion (i.e. pain killers),
* Participation in other clinical trials, where at least one dose of study drug was administered, within 90 days preceding the screening phase,
* Blood drawn within 30 days prior to inclusion in this study (more or equal to 300 mL),
* Positive results from pregnancy test in female volunteers,
* Lactation in female volunteers,
* Hypotension or hypertension in medical history,
* Narcotic and alcohol addiction or abuse,
* Positive results of HBsAg, anti-HCV or anti-HIV tests,
* Positive drug screen or alcohol breath tests,
* Subjects who adhere to a special diet (e.g. low calories, vegetarian,etc.).

Primary outcomes:
measure: Determination of maximum tolerated dose (MTD) or administration of the maximum dose provided in the protocol after single and multiple oral administration of IMP.
timeFrame: up to 48 hours after single administration of IMP in PART A and up to 48 hours after the last IMP administration in PART B
measure: Safety and tolerability of IMP after single and multiple oral administration
timeFrame: up to 14 days in PART A and up to 28 days in PART B of the study
Secondary outcomes:
measure: Cmax - maximum plasma concentration
timeFrame: up to 48 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 8 in PART B and up to 48 hours after the last IMP administration on Day 14 in PART B
measure: AUC(0-48) - area under the plasma concentration - time curve from time 0 to 48h after IMP administration
timeFrame: up to 48 hours after administration of IMP in PART A and after the IMP administration determined on Day 14 in PART B
measure: AUC(0-24) - area under the plasma concentration - time curve from time 0 to 24h after IMP administration
timeFrame: up to 24 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1 and 8 in PART B
measure: AUC(0-inf) - area under the plasma concentration - time curve from time 0 to infinity time
timeFrame: up to 48 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 8 in PART B and up to 48 hours after the last IMP administration on Day 14 in PART B
measure: Tmax - time to reach maximum concentration
timeFrame: up to 48 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 8 in PART B and up to 48 hours after the last IMP administration on Day 14 in PART B
measure: Kel - terminal elimination rate constant
timeFrame: up to 48 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 8 in PART B and up to 48 hours after the last IMP administration on Day 14 in PART B
measure: T1/2 - The plasma elimination half-life
timeFrame: up to 48 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 8 in PART B and up to 48 hours after the last IMP administration on Day 14 in PART B
measure: C (1,t) - CPL207280 concentration
timeFrame: Determined on Day 2, 3, 4, 5, 6, 7, 9, 10, 11, 12 and 13 in PART B
measure: C (Tmax, t) - CPL207280 concentration
timeFrame: Determined on Day 2, 3, 4, 5, 6, 7, 9, 10, 11, 12 and 13 in PART B
measure: Glucose AUEC -area under the effect-time curve after IMP administration
timeFrame: up to 6 hours after administration of IMP in PART A and up to 6 hours after the IMP administration determined on Day 1, 8,14 in PART B
measure: Insulin AUEC -area under the effect-time curve after IMP administration
timeFrame: up to 6 hours after administration of IMP in PART A and up to 6 hours after the IMP administration determined on Day 1, 8,14 in PART B
measure: Proinsulin AUEC -area under the effect-time curve after IMP administration
timeFrame: up to 6 hours after administration of IMP in PART A and up to 6 hours after the IMP administration determined on Day 1, 8,14 in PART B
measure: C-peptide AUEC -area under the effect-time curve after IMP administration
timeFrame: up to 6 hours after administration of IMP in PART A and up to 6 hours after the IMP administration determined on Day 1, 8,14 in PART B
measure: Glucagon AUEC -area under the effect-time curve after IMP administration
timeFrame: up to 6 hours after administration of IMP in PART A and up to 6 hours after the IMP administration determined on Day 1, 8,14 in PART B
measure: AUC(0-tau, t)- area under the curve of plasma concentration vs time, from time point zero up to the time of 24h in day t
timeFrame: up to 24 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 8 and 14 in PART B
measure: Cav,t, averate IMP concentration on day t
timeFrame: up to 24 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 8 and 14 in PART B
measure: Fluctuation
timeFrame: up to 24 hours after administration of IMP in PART A and up to 24 hours after the IMP administration determined on Day 1, 8 and 14 in PART B
Other outcomes:
Locations:
city: Kajetany
country: Poland
facility: BioResearch Group Sp. z o.o.
state: Nadarzyn
Study officials:
References:
citation: Bazydlo-Guzenda K, Buda P, Matloka M, Mach M, Stelmach F, Dzida R, Smuga D, Hucz-Kalitowska J, Teska-Kaminska M, Vialichka V, Dubiel K, Kaminska B, Wieczorek M, Pieczykolan J. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals. Mol Pharmacol. 2021 Oct;100(4):335-347. doi: 10.1124/molpharm.121.000260. Epub 2021 Aug 4.